cefiderocol fetroja Search Results


cefiderocol fetroja solutions  (Shionogi)
86
Shionogi cefiderocol fetroja solutions
Cefiderocol Fetroja Solutions, supplied by Shionogi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cefiderocol+fetroja/pm40807247-168-2-12?v=Shionogi
Average 86 stars, based on 1 article reviews
cefiderocol fetroja solutions - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
antimicrobial drugs  (Shionogi)
86
Shionogi antimicrobial drugs
Respondents’ views on whether the UK ‘subscription-type’ payment model should be expanded to cover additional therapeutic areas <t>(non-antimicrobial</t> = monoclonal antibodies, phages, anti-virulence agents); ( n = 43).
Antimicrobial Drugs, supplied by Shionogi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cefiderocol+fetroja/pmc12910370-33-11-15?v=Shionogi
Average 86 stars, based on 1 article reviews
antimicrobial drugs - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
cefiderocol  (Aladdin Scientific Corporation)
N/A
Cefiderocol (S-649266) is a siderophore cephalosporin which has a potent activity against a broad range of aerobic Gram-negative bacterial species with MIC50s of 2 μg/mL or less.
   Buy from Supplier

Image Search Results


Respondents’ views on whether the UK ‘subscription-type’ payment model should be expanded to cover additional therapeutic areas (non-antimicrobial = monoclonal antibodies, phages, anti-virulence agents); ( n = 43).

Journal: JAC-Antimicrobial Resistance

Article Title: Exploring the perspectives of antimicrobial stewardship pharmacists in England on the subscription model for antimicrobial drugs

doi: 10.1093/jacamr/dlag018

Figure Lengend Snippet: Respondents’ views on whether the UK ‘subscription-type’ payment model should be expanded to cover additional therapeutic areas (non-antimicrobial = monoclonal antibodies, phages, anti-virulence agents); ( n = 43).

Article Snippet: The model pilot launched in July 2022 initially included two new antimicrobial drugs [cefiderocol (Fetroja; Shionogi) and ceftazidime-avibactam (Zavicefta; Pfizer)] and marked a significant step towards innovative drug funding., However, the journey has not been without hurdles.

Techniques: Bioprocessing

Percentage agreement on scenarios justifying empirical antimicrobial use. This bar chart displays the percentage of respondents who agreed that various risk factors would justify the empirical use of antimicrobials introduced via a ‘subscription-type’ payment model ( n = 43; 95% CI). CRB, carbapenem-resistant bacteria.

Journal: JAC-Antimicrobial Resistance

Article Title: Exploring the perspectives of antimicrobial stewardship pharmacists in England on the subscription model for antimicrobial drugs

doi: 10.1093/jacamr/dlag018

Figure Lengend Snippet: Percentage agreement on scenarios justifying empirical antimicrobial use. This bar chart displays the percentage of respondents who agreed that various risk factors would justify the empirical use of antimicrobials introduced via a ‘subscription-type’ payment model ( n = 43; 95% CI). CRB, carbapenem-resistant bacteria.

Article Snippet: The model pilot launched in July 2022 initially included two new antimicrobial drugs [cefiderocol (Fetroja; Shionogi) and ceftazidime-avibactam (Zavicefta; Pfizer)] and marked a significant step towards innovative drug funding., However, the journey has not been without hurdles.

Techniques: Bacteria